Effect of treatment on miRNA levels on OCD
- Conditions
- Health Condition 1: F429- Obsessive-compulsive disorder, unspecified
- Registration Number
- CTRI/2022/04/041628
- Lead Sponsor
- Medical Research Unit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
i.Meeting the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) presented by the American Psychiatric Association (Washington, D.C., USA)
ii.Aged between 16 and 50 years old
iii.A YaleBrown Obsessive-Compulsive Scale (Y-BOCS) score >16 points; for simple obsessive or forced behavior, a Y-BOCS score >8 points.
iv.No other major mental illnesses.
v.No history of psychiatric drug use.
vi.Give written informed consent.
i.A history of organic brain disease or serious physical illness, symptoms of psychosis, or a history of other mental illnesses
ii.Severe depression (a Hamilton Depression Rating Scale (HAMD) score >35 points)
iii.Second-generation with a family history of mental illness.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To assess alteration in plasma levels of miRNA-132 in patients with obsessive-compulsive disorder before and after treatment <br/ ><br>2.To assess alteration in plasma levels of miRNA-134 in patients with obsessive-compulsive disorder before and after treatmentTimepoint: 24 weeks
- Secondary Outcome Measures
Name Time Method 1.To find correlation between levels of miRNA-132 and clinical indicators before and after treatment. <br/ ><br>2.To find correlation between levels of miRNA-134 and clinical indicators before and after treatment.Timepoint: 24 weeks